Lupin gets clearance from USFDA for Pithampur unit
DSIJ Intelligence / 29 Jul 2017
Lupin is an innovation-led transnational pharmaceutical company developing and delivering a wide range of branded and generic formulations, biotechnology products and APIs globally.
Pharmaceutical major Lupin announced on Friday the successful completion of a GMP inspection as well as a PAI inspection (Prior Approval Inspection) carried out by the US FDA at its Pithampur manufacturing facility - Unit 1 without any observations.
The inspection was started on Monday, July 24, 2017.
For the financial year ended March 31, 2017, Lupin’s consolidated sales and net profit stood at Rs 171,19.8 crore and Rs 2,557 crore respectively.
Lupin is an innovation-led transnational pharmaceutical company developing and delivering a wide range of branded and generic formulations, biotechnology products and APIs globally.
The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, GI, anti-infective and NSAID space and holds global leadership position in the anti-TB segment.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.